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Abstract 
 
放射線治療は，手術，化学療法と並んで主要な治療手段として発展してき
た。近年，がん治療患者の半数以上が一連の治療過程において放射線治療を受
けている。加えて，放射線治療は長年にわたって根治的な治療手段としてのみ
ならず，緩和的な治療手段として実践されてきた。放射線治療の理論的な研究
は，古くから放射線生物学に基づく基礎実験の結果とともに発展し，とりわけ
放射線に対する細胞応答に関する機序解明が重要とされてきた。近年の分子生
物学の発展に伴い，放射線に対する細胞の分子生物学的な作用機序が次第に解
明されつつある。しかし，放射線生物学を視野に入れた放射線治療効果の改善
ならびに臨床応用に関しては多くの課題が残されている。 
X 線の発見以来，放射線治療は 120 年近い歴史があるが，その生物学的影響
やプロセスは非常に複雑であり，臨床では組織反応の定量化（NSD や TDF）
が治療成績改善に重要な役割を果たしてきた。1980 年代以降，より正確な放
射線治療効果の評価や予測において LQ モデルが提唱され，現在もなお臨床で
幅広く応用されている。しかし，低酸素細胞や腫瘍幹細胞の存在，空間，時間
的に不均一な放射線照射，バイスタンダー効果，細胞周期，遺伝子変異等に伴
う放射線感受性の違いに対する課題が残されている。 
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 本研究では，様々な環境下における細胞間放射線感受性の不確かさを定量的
に評価し，また臨床の放射線治療ではどの程度影響しうるのか，治療計画を通
じて応用可能とすることを目標とする。しかし，この目標を全て達成するに
は，細胞の放射線感受性は，細胞特性（細胞周期，細胞生存環境，病理組織の
違い，遺伝子タイプ等）および放射線特性（線種，線質，線量率（照射時
間），線量分布）の違いによってどのように影響するのか解明することが重要
とされる。 
本研究では，幾つかの制限を設けた上で，乳がんマウス由来のEMT6細胞を用
いて基礎実験を行い，生存環境（酸素分圧）の違いに伴う放射線感受性の変化に
ついてLQモデルを利用して解析した。方法は，培養したEMT6細胞（2×106 cells）
を試験管に入れ，常酸素群，低酸素群として異なる放射線量（4 Gy-28 Gy）で
X線照射（150 kV，4 Gy/min）した。このとき，低酸素細胞は，95 %窒素，5 %
二酸化炭素の混合ガスを30分曝露させて作成した。また，低酸素群に増感剤
（etanidazole）を加えた群についても，同様に実験し，コロニーアッセイを行
い，細胞生存率曲線から生物物理モデルパラメータ（𝛂成分，𝛃成分，𝑫𝟓𝟎，𝛄）
を導出した。解析結果から，𝛂成分のパラメータ（平均値±1標準偏差）は，常酸
素細胞，低酸素細胞，低酸素細胞に増感剤を加えたもので，それぞれ0.257 ± 
0.188 Gy-1，0.078 ± 0.080 Gy-1，0.182 ± 0.116 Gy-1となった。同様に，𝛃成分の
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パラメータは，それぞれ0.0159 ± 0.0208 Gy-2，0.0076 ± 0.0113 Gy-2， 0.0062 
± 0.0077 Gy-2となった。𝑫𝟓𝟎パラメータは，それぞれ3.2 ± 2.5 Gy，6.4 ± 2.7 Gy，
3.7 ± 1.4 Gyとなった。𝛂および𝑫𝟓𝟎の値は明らかに常酸素群と低酸素群で異な
り，また同一群でも多少のばらつきを持ち，生存環境の違いだけでなく，同じ環
境の細胞間でも放射線感受性は大きく変動することが明らかとなった。  
続いて，上記の課題に対する検討として，臨床で用いられる 3 次元治療計画
装置（Eclipse ver.11.0，Varian medical systems，US）においてファントムお
よび患者模擬データによる臨床治療計画から，腫瘍パラメータである𝛂/𝛃比, 𝛄, 
𝑫𝟓𝟎の違いや変動が腫瘍局所制御率（TCP）に，また正常臓器パラメータである
の𝛂/𝛃比，n 値，m 値が正常臓器副作用発生率（NTCP）にどのような影響を及
ぼすかを検討した。このとき，治療ビームは臨床で用いられている 6 MV X 線
のデータ（Novalis-Tx，BrainLab，US)を利用した。線量分割スケジュールは，
70 Gy/35 fr，72 Gy/36 fr，74 Gy/37 fr，76 Gy/38 fr，78 Gy/39 fr，72 Gy/40 
fr，73.8 Gy/41 fr，45.6 Gy/42 fr，77.4 Gy/43 fr，79.2 Gy/44 fr，81 Gy/45 fr，
52.5 Gy/20 fr，57 Gy/19 fr，60 Gy/20 fr，62 Gy/20 fr，56 Gy/16 fr，63.2 Gy/20 
fr，66 Gy/22 fr，35 Gy/5 fr，37.5 Gy/5 fr，40 Gy/5 fr による複数パターンで解
析を行い，すべて，1 日 1 回による週 5 日間照射を想定した。また，解析の際，
線量分割スケジュールの違いを考慮するため生物学的等価線量（BED）を用い
 iv 
 
た。結果として，腫瘍の TCP は BED10（通常，腫瘍に対する生物学的等価線量
とされる）に依存して増加し，𝛂/𝛃比, 𝛄, 𝑫𝟓𝟎はいずれも値が小さいほど低下す
る傾向があった。𝛂/𝛃比, 𝛄, 𝑫𝟓𝟎の変動に対する TCP の影響は，𝛂/𝛃比, 𝛄に比
べて𝑫𝟓𝟎の方が強く生じた。正常臓器の NTCP は BED3（通常，正常臓器に対す
る生物学的等価線量とされる）に依存して増加し，m 値が大きいほど，n 値が
小さいほど上昇する傾向があった。𝛂/𝛃比，m 値， n 値の変動に対する NTCP
の影響は，高線量寡分割プロトコルにおいて m 値，n 値に比べて𝛂/𝛃比の方が
強く生じた。これらの結果から，腫瘍および正常臓器への影響は，線量分割スケ
ジュールの違い，生物学的パラメータの値や変動に依存することが明らかとな
り，基礎実験で得られた知見とともに更なる治療計画の最適化へのアプローチ
に向けて応用可能な結果が得られた。 
本研究では，提案手法に基づいて，乳がんマウス由来の EMT6/KU 細胞を用
いて基礎実験を行い，生存環境（酸素分圧）の違いに伴う放射線感受性の変化
について解析した。また，それらの結果を踏まえて，臨床治療計画において，
生物物理モデルを適用し，各種パラメータ値の変動を加味した治療効果予測に
ついて提案した。治療効果予測が可能な生物物理モデルを用いた臨床治療計画
の最適化は，個別化治療（テーラーメイド医療）において重要とされる，しか
し，結果が示すようにパラメータ値の信頼性に強く依存して予測結果は変化す
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るため，パラメータ値の決定精度（各種検査法）の確立とともに，不確かさを
含む評価法もまた重要であることが明らかとなった。  
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Chapter 1   
Introduction 
   
Radiotherapy has developed as primary treatment options for cancer 
along with surgery and chemotherapy.  Recently, more than half of all 
cancer patients have receiving radiation therapy during their course of 
illness (1, 2).  In addition to the radical therapeutic use of radiotherapy, 
many patients have been received palliative treatment by radiation therapy 
for many years.   
  Theoretical studies based on the in vitro experiments in radiobiology have 
contributed to the development of radiotherapy.  There is obvious that 
radiobiology has developed with valuable data on its mechanisms of effects 
of cells by radiation.  However, few of these still have led to demonstrable 
clinical gains.  In the field of clinical radiotherapy, the conversion formulae 
based on the linear quadratic (LQ) equation (3) often has been used in the 
choice of specific protocols.  However, the equation also has been limited by 
the inadequacy of the theoretical and experimental models so that it always 
needs to rely on the results of clinical trials.   
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  Ionizing radiation consisting of high energy photons and electrons 
produced by 4-21 MV linear accelerator is the most commonly used for the 
radiotherapy in a clinical situation.  Range from less than 100 keV to order 
of MeV electrons arose from the molecules within cells, which is in the body 
through the interactions with the incident ionizing radiation, cause most of 
the biological damage known as DNA breakage, cell killing (apoptosis) and 
so on.  However, for many years, little attention was paid towards 
differences in the mechanisms or types of cell death after irradiation.  
Because cell death itself is typically very hard to assess, quantification of 
cell death by ionizing radiation is highly complicated by the fact that cells 
die at various times after irradiation, and sometimes surviving cells 
continue to proliferate.  Many researchers have focused on assessing 
clonogenic cell survival, which specifies as the ability of a cell to proliferate 
indefinitely after irradiation.  From a macroscopic viewpoint, it can be clear 
that the surviving cells would decrease by a certain amount of radiation 
dose.  In contrast, it is challenging that from a microscopic viewpoint, no 
one still predict which cell die or survive by radiation.  These uncertain 
phenomena would be needed a much more robust and relevant parameter to 
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assess radiation effect stochastically since any cell that retains proliferative 
capacity can cause failure to cancer treatment. 
  Consequently, it has well known that by far the most efficient way of 
improving the outcome of the treatment is to practice the quality assurance 
for the precise prescription of radiation dose and the delivery techniques to 
the localized tumour.  These developments undoubtedly lead to further 
improvements in tumour control rates and reductions in morbidity.  
However, it is critical to consider not only the specific types of cell death that 
lead to the destruction of the cell but also to evaluate the uncertainties of 
cell death or cell survival by radiation.  In this thesis, we investigate the 
distribution of uncertainty of cell survival due to radiation and application 
of treatment planning. 
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Chapter 2 
Definition of radiation effects and biophysical models 
 
2-1. Radiation effects 
2-1-1. The time frames for effects of radiation 
  The irradiation effects of radiation to any biological system generate 
several processes that differ considerably from the time frames (4, 5) are 
mainly divided into three processes (Figure 1).  
  The first, the physical process consists of interactions between charged 
particles and the atoms composed of molecules in tissue.  A charged 
particles, which are commonly secondary electrons produced in the body by 
a high energy photon beam in modern clinical radiotherapy, takes about 10-
18 second to traverse the DNA molecule in tissue and about 10-14 second to 
pass through a cell.  If these charged particles are sufficiently energetic, 
they interact mainly with orbital electrons within an atom (i.e. it make 
excitation or ionization) in a cell and occur a cascade of ionization events.  
For 1 Gy of radiation absorbed dose, there are more than 105 ionizations 
within the volume of every cell of diameter, which is about 10 μm. 
 5 
 
  The second, the chemical process consists of the period in which these 
ionized and excited atoms/molecules interact with other cells as a chemical 
reaction.  Ionization and excitation of orbital electrons in atoms and 
molecules cause the cut of chemical bonds of them and the isolated 
molecules known as free radicals form simultaneously.  Free radical are 
highly reactive, and their reactions complete within approximately 1 ms 
(millisecond) of radiation exposure.  
  The third, the biological process consists of all subsequent processes after 
chemical phases, such as repair processes, further cell divisions, mitotic 
death, apoptosis, effects on organs and carcinogenesis.  These subsequent 
processes begin with enzymatic reactions of that act on the repair of 
residual chemical damage by radiation.  Double-strand breaks (DSB) are 
more frequent in radiation-induced damage than single strand breaks 
(SSB), which are more often in normal DNA damage.  In the case of small 
doses of radiation exposure, most of the damages in DSB are repaired.  
However, some lesions would fail to repair of DSB and to lead to mutations 
or loss of genetic information or cell death as higher doses of radiation 
exposure.  The subsequent unrepairable damages in DSBs would cause the 
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early symptoms as normal tissue response from several weeks after 
radiation exposure.  More than several months after irradiation, delayed 
reactions might appear as more serious damages of organs including second 
cancers (i.e. radiation carcinogenesis). 
2-1-2. Dose response curves of cells by radiation 
  The response of radiation damage in irradiated normal tissue increases as 
the amount of radiation dose, and it has a peak and decline (dotted line in 
Figure 2a).  The appearance of the peak changes with radiation dose and 
dose rate so that this would lead to temporal uncertainties of the response 
in the tissue.  Some early tissue responses show a trend of the cumulative 
curve that has a plateau, and the height of the plateau is a good index of the 
total response to the tumour and the normal tissue.  Meanwhile, the 
delayed tissue responses are dynamic so that the cumulative curve would 
creep up even after irradiation.  Cell survival curves are further examples 
of dose-response curves that often present in the result of fundamental 
experiments in radiobiology.  The shape of the curve on the dose scale 
indicates the radiation sensitivity of the cells in the tumour and normal 
tissue.  The steepness of the curve also indicates the absolute change in 
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response, which accompany an increase or decrease in radiation dose as 
characteristics of radiation sensitivity. 
  It is a well-known fact that in radiation therapy that multiple 
fractionated radiation doses irradiated over a period of a few weeks in 
common result a better therapeutic response than single fraction dose.   
Experimentally, altered dose fractionation (e.g. number of fractionation or 
fraction size, dose rate) in multiple studies demonstrated the different 
therapeutic effect regarding an iso-effect.  The iso-effect means how the 
total radiation dose for the chosen level of effect varies with dose schedule 
with consideration of some upper limit of tolerance of the tissue (6, 7). 
2-1-3. The approach to cancer therapy by radiation 
If the curve for tumour response is much superior to that for normal tissue, 
there is a therapeutic advantage by radiation.  As the prescription dose 
increase, not only the tumour but the normal tissue response is expected to 
rise.  If we can control the tumour and the normal tissue response, sigmoid 
relationships to the amount of dose would be formed (Figure 2b).  The 
relative shift of the response curves for the tumour and normal tissues should 
usually be different.  However, to minimize the normal tissue damage 
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considering with tolerance level, the response curves between tumour and 
normal tissue should be interspatial combined with drug or state of the art 
irradiation techniques.  The concept of cancer therapy by radiation is to 
optimize the tumour control dose and the tolerance dose in normal tissue 
spatially and temporarily (i.e. total dose, the number of fractionation and dose 
rate).  
2-1-4. Radiation-induced DNA damage 
Ionizing radiation consisting of electromagnetic radiation, usually photons 
and electrons, is most commonly used in the treatment of patients with 
radiotherapy.  The maximum energy of 4-10 MV photons produced by the 
acceleration of electrons using a linear accelerator that typically used in 
Japanese radiotherapy departments.  The major effects of the radiation are 
its ability to ionize, or eject electrons, from atoms and molecules within cells 
of which it composes the tumour and the normal tissues.  Most biological 
damage in the cell caused by the ejected electrons that arise further 
ionizations in molecules until they slow down and stop.  At the termination 
of the end tracks, electron interactions with other molecules become more 
frequent and cause clusters of ionizations.  Some of the clusters directly 
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occur in DNA of a cell, and the cell loses function to repair the damage (Figure 
3).  
Ionized molecules of water inside cells produced by electrons are very 
reactive and can lead to the breaking of chemical bonds.  This phenomenon 
can also disrupt the structure of DNA, which may cause severe damages if 
not repaired adequately at the time.  The result of permanent damage to 
DNA can be often fatal for the cell.  Cellular DNA comprises two opposing 
strands linked by hydrogen bonds and forming a double helical structure.  
Each strand composed of a linear chain of the four bases, adenine (A), cytosine 
(C), guanine (G) and thymine (T).  Some reports show that a radiation dose 
of one gray (1 Gy) produces 105 ionizations per cell, which cause about 1000-
2000 DNA initial single strand breaks (SSBs) and 25-40 DNA initial double 
strand breaks (DSBs) (8, 9).  
Because of the functional importance of DNA, the cells and the organisms 
have developed a complex series of processes and signal pathways for 
repairing those inside of DNAs from oxidation and ionizing radiation (10).  
These include different forms of DNA repair such as base excision repair 
(BER), single-strand break repair (SSBR), double strand breaks repair of 
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homologous recombination (HR) and non-homologous end-joining (NHEJ).  
This kind of repair forms has coped with the different forms of DNA damage 
induced by various agents.   
2-1-5. Induction of cell death and repair after irradiation 
The treatment of radiotherapy is to cause the death of individual tumour 
cells in the malignant lesion.  The radiobiological effects of cell death are 
considerably affected by radiation dose and signal pathways within the 
cellular response including DNA damage by radiation.  Because of 
differences between the types of cells, the eventual cell death can also 
different among those cell types.  Quantification of cell death is highly 
complicated because the cells die at various timing after irradiation such one 
or two cycles around their specific cell cycle.  Instead, the rest of surviving 
cells continue to proliferate.  However, it is clear that radiation can kill cells 
by various mechanisms.  Apoptosis, well known as a programmed form of 
cell death by radiation, results in self-destruction and removal of the cell (11).  
Also, these genetically controlled programs and several other pathways under 
genetic control have been identified such as autophagy, senescence, and 
necrosis that contribute to preventing further proliferation (12).    
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2-2. Biophysical models 
2-2-1. Target theory 
The prediction how radiation might kill cell is an important issue in specific 
targets accounting for the measurement of radiation sensitivity of the cell or 
results of radiotherapy.  Historically, there are two versions of target 
theories that had used as classic calculation models.  The first theory is that 
just one hit by radiation on a single sensitive target would lead to the death 
of the cell (i.e. it is called single target single hit model).  In this theory, the 
cell survival exponentially decreased.  Using Poisson statistics, we can 
define the probability (p) of cell survival during irradiation with many hits on 
different cells by the following equation (Figure 4a). 
p (survival) = p (0 hits) = 𝑒(−𝐷/𝐷0)     (2.1) 
where 𝐷0 means the dose that gives an average of one hit per target.  𝐷/𝐷0 
means the average number of hits per target.  In semi-logarithmic plot, this 
curves show straight line and they are usually found for the inactivation of 
viruses and bacteria, however they can fit only for some very sensitive 
mammalian cells or in case of using high LET radiations. 
The second theory is that the cell survival curves have some shoulder to fit 
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mammalian cells’ survival curve, which called multi-target single hit model.  
In this extended model, just one hit by radiation on each of n targets in the 
cell is required for death of the cell.  Similar to the equation (2.1), using 
Poisson statistics, we can define the probability (p) of cell survival during 
irradiation by the following equation according to some hypothesizes (Figure 
4b). 
p (0 hits on a specific target) = 𝑒(−𝐷/𝐷0)    (2.2) 
Then 
p (specific target inactivated) = 1 − 𝑒(−𝐷/𝐷0)   (2.3) 
If there are n targets in the cell, 
p (all n target inactivated) = {1 − 𝑒(−𝐷/𝐷0)}
𝑛
   (2.4) 
Therefore, 
p (not all targets inactivated) = 1 − {1 − 𝑒(−𝐷/𝐷0)}
𝑛
   (2.5) 
where multi-target single hit survival curves have a shoulder so that the 
quasi-threshold dose (𝐷𝑞) is defined.  The relationship between 𝐷𝑞, n and 𝐷0 
is as following equation. 
𝐷𝑞 = 𝐷0log𝑒𝑛                    (2.6) 
 The multi-target survival curves have proved useful for describing 
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mammalian cells at high doses.  However, they do not fit well at a lower 
dose in clinical radiotherapy.  
2-2-2. The linear quadratic model 
The formula of second-order polynomial fitting with a zero constant term 
to ensure survival fraction of 1 at zero doses is termed as linear-quadratic 
(LQ) model.  It is not only the simplest formula mathematically but also it 
can be explained reasonably from the viewpoint of radiobiological 
mechanisms.  Then, we can define the probability (p) of cell survival (S) 
during irradiation by the following equation (Figure 5). 
−ln(𝑆) = 𝛼𝐷 + 𝛽𝐷2             (2.7) 
𝑝(𝑠𝑢𝑟𝑣𝑖𝑣𝑎𝑙) = 𝑒(−𝛼𝐷−𝛽𝐷
2)         (2.8) 
The explanation of radiobiological mechanisms in LQ model is that the 
linear component might result from single-track events (SSB) while the 
quadratic component might arise from the two-track event (DSB).  This 
interpretation supposed from the outcome of a dose-rate effect shows that the 
dose rate affects cell survivals due to the change of probability of both events 
(SSB and DSB). 
The simple LQ model gives a good description in low dose prescription in a 
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clinical situation (about 1.5-3 Gy).  The shape is determined by the ratio of 
α  and β , which consist of the linear contribution to damage ( α𝐷 ) and 
quadratic contribution ( β𝐷2 ).  The response curve of cells to high LET 
radiation such as α particles or carbon-ions is usually a steep and almost 
exponentially straight line with high α/β ratio. 
2-2-3. Tumour control probability (TCP) model 
  Dose response curves of cells by radiation have a sigmoid function with the 
incidence of radiation effects tending to zero as the dose tends to zero and 
tending to 100 percent at large doses.  Munro and Gilbert (13) firstly 
formulated the target-cell hypothesis of tumour control that based on the 
result of random nature of cell killing by radiation as a probability of tumour 
cure after irradiation of tumour cells.  More accurately, this calculated 
probability is only related to the average number of clonogens surviving per 
tumour. 
  The Poisson distribution is appropriate for many processes involving the 
counting of random events such an evaluation of radioactivity or the number 
of tumour cells forming colonies.  When describing tumour control 
probability (TCP), it is the probability of zero surviving clonogens in a tumour 
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that is of interest. Moreover, that is the zero-order term of the Poisson 
distribution and if 𝑁0 denotes the number of clonogens per tumour before 
irradiation and 𝜆 (i.e. 𝑒(−𝐷/𝐷0) in equation (2.1) of single target single hit 
model) denotes the probability of average number of survived clonogens per 
tumour after irradiation.  Therefore, the value of TCP could be predicted 
from equation (2.9).  
TCP = 𝑒−𝑁0𝜆            (2.9) 
  Furthermore, if the average number of surviving clonogenic cells per 
tumour has the negative exponential function of dose, the TCP would be 
formed sigmoidal response curve as similar to the collective tumour response 
as shown in Figure 2b.  The curve could be explained only by the random 
nature of cell killing after irradiation.  Therefore, the variation of sensitivity 
of tumours is not be considered.  If we replace the simple exponential curve 
of 𝜆 in equation (2.9) to the probability of an average number of survived 
clonogens per tumour in LQ model as shown in equation (2.8), the standard 
model of TCP in LQ model is expressed as following equation. 
  TCP = 𝑒−𝑁0𝑒
(−𝛼𝐷−𝛽𝐷2)
          (2.10) 
  Here, 𝑁0  means a function of tumour volume and the clonogenic cell 
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density (i.e. clonogens/cm3 in the tumour).  However, because the model 
parameter will be influenced by biological and irradiated dose heterogeneity 
in the tumour, it could not be practically used in clinical situation.  
2-2-4. Normal tissue complication probability (NTCP) model 
  In modern radiotherapy, the development of treatment techniques often 
makes possible to avoid normal tissues irradiation preferably.  However, the 
optimized strategies have led to non-uniform partial organ irradiation of 
normal tissues.  
The normal tissue complication probability (NTCP) model was proposed by 
Lyman (14) for prediction of side effect stochastically by radiotherapy as a 
function of radiation dose in a partial organ volume.  According to the model, 
the NTCP for the normal tissues can be calculated as following equations. 
NTCP =
1
√2𝜋
∙ ∫ 𝑒
−(−
1
2
𝑥2)𝑑𝑥
𝑢(𝐷,𝑉)
−∞
          (2.11) 
where, the dependence of dose and volume is in the upper limit of the 
integral. 
u(𝑑, 𝑉) =
𝐷−𝐷50(𝑉)
𝑚∙𝐷50(𝑉)
            (2.12) 
The equation of volume dependence of the 𝐷50 can express as the following 
relationship. 
 17 
 
𝐷50(𝑉) =
𝐷50(1)
𝑉𝑛
            (2.13) 
A closer inspection of these three equations shows that there are two 
independent variables, 𝐷 and V, and three model parameters, m, 𝐷50(1) and 
n.  𝐷50(1) is the uniform total radiation dose producing a 50 percent incidence 
of the specific side effect if the whole organ is receiving this radiation dose.  
The volume exponent, n, is the volume effect to the radiation dose.  The third 
parameter, m, is inversely related to the steepness of the radiation response 
curve.   
The Lyman’s NTCP model assumes that one part of the normal tissue 
receives a uniform radiation dose while no dose for the rest of them.  
Therefore, its use should be coupled with a method of reducing the non-
uniform dose distribution across the tissue to corresponding effective volume 
or effective uniform dose (15).  Although dosimetric and biological 
heterogeneity could cause the radiation response curve to be shallower by 
improvement of irradiation techniques, due to the complexity of the models 
and the uncertainties in the model parameters, NTCP modeling has not been 
widely applied to practical radiotherapy. 
2-2-5. Steepness of radiation response curves in the tumour and normal 
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tissues 
  The most convenient way to quantify the steepness of the radiation 
response curve is using the ‘γ’ (i.e. gradient of the curves) proposed by Brahme 
(16).  This measure has a very simple interpretation that the fraction of 
increase response by irradiated dose.  The definition of ‘γ’ is expressed as 
following equation. 
γ ≈ lim
Δ𝐷→0
𝑃(𝐷+Δ𝐷)−𝑃(𝐷)
∆𝐷
= 𝐷
∆𝑃
∆𝐷
= D ∙ P′(𝐷)         (2.14) 
where, P(𝐷) means the response as a function of dose, and ∆D means a 
small increment in dose.  Therefore, ‘γ’ is multiplier that converts a relative 
change in dose into a change of TCP by following equation.   
∆𝑃 ≈ 𝛾 ∙
∆𝐷
𝐷
            (2.15) 
  The value of ‘γ’ depends on the response level typically written with an 
index indicating the steepness of radiation response curves, usually at the 50 
percent level as ‘γ50’.  However, because the steepness of radiation response 
curve varies at another level, assuming a fixed value for ‘γ’ is sensitive to 
uncertainty for calculation using the TCP/NTCP model.    
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Chapter 3 
Radiosensitivity uncertainty evaluation for the  
in vitro biophysical modeling of EMT6 cells 
 
3.1. INTRODUCTION 
Recently, there have been rapid advances in radiotherapy technologies, 
such as volumetric modulated arc therapy (VMAT), stereotactic body 
radiotherapy (SBRT), and image-guided radiotherapy (IGRT) (17-21).  
Because clinical failures after radiation therapy due to hypoxia, intrinsic 
radioresistance, and cellular proliferation are known to induce genetic 
changes, radiobiological parameters and molecular biology data from tumour 
and critical organs could be used in clinical practice for better treatment (22, 
23). 
Applying biophysical models to treatment planning in radiotherapy, several 
researchers reported about the feasibility of prediction or evaluation for 
tumour controllability and toxicity in normal tissues in a clinical situation (24, 
25).  Radiation sensitivity is usually affected by cell heterogeneity and 
radiosensitizing agents (26-28).  Nevertheless, the uncertainty surrounding 
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radiosensitivity because of the factors are not well accounted for in 
biophysical modeling (29, 30).  In particular, hypoxic cells in the tumours 
lead to increased radioresistance of clonogens, which affects the clinical 
outcome (31, 32).  Etanidazole (ETZ) and misonidazole are well known 
hypoxic cell radiosensitizers but have had limited beneficial impact on 
radiotherapy because of side effects such as neurotoxicity (33).  For 
biophysical evaluation of physical dose prescriptions, including dose fractions 
and biologically equivalent dose (BED), the linear-quadratic (LQ) model 
based on intrinsic radiosensitivity is commonly used in practical radiotherapy 
(34).  However, to make precise predictions on outcomes after radiotherapy 
for the treatment planning stage, the other uncertainties of radiation 
sensitivity would need to be carefully considered. 
We evaluated the distribution of uncertainty of cell survival due to 
radiation and assessed the predictions of tumour response using three 
different in vitro experimental cell cultures.  We then discussed the 
relationship between in vitro radiosensitizing activities and uncertainties in 
characteristics of cell survival using radiobiological parameters. 
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3-2. MATERIALS AND METHODS 
3-2-1. Development of the experimental system 
In this experimental system, we have synthesized ETZ and have 
maintained EMT6/KU mouse mammary tumour cells in Eagle’s MEM 
medium (Sigma-Aldrich Japan, Tokyo, Japan) supplemented with 10% fetal 
bovine serum (JR Scientific, Inc., Woodland, CA, USA) in our laboratory.  For 
single cell experiments, exponentially growing cells were harvested at 
normoxic cell culture by trypsinization in the dishes, and suspended in test 
tubes containing 1 ml of E-MEM (2×106 cells/ml).  In the hypoxic cultures, 
they were treated with 95% N2–5% CO2 gas for 30 min.  In vitro 
radiosensitization was also measured in single EMT6/KU cells by adding 
radiosensitizer under hypoxic conditions. 
3-2-2. Radiation procedure 
X-ray irradiation was carried out using an X-ray unit (Hitachi X-ray unit, 
model MBR-1505R2) with 0.5 mm Al and 1.0 mm Cu filter (150 kV, 4 Gy/min).  
In in vitro assays, cells on the dish were irradiated with 4–28 Gy.  After 
irradiation, colony formation assays were performed. 
3-2-3. Biophysical modeling 
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To determine cell survival rate as to tumour control, we use the LQ 
formalism that reflects the various tumour parameters.  The probability of 
cell survival in colony by single fraction dose is given by equation (3.1), 
𝑁 = 𝑁0𝑒𝑥𝑝(−α𝐷 − β𝐷
2)      (3.1) 
where 𝑁  equals the number of surviving cells, 𝑁0  equals the number of 
tumour cells at the start of the experiment, 𝛼 and β equal the estimates of 
radiosensitivity, and 𝐷 equals the total dose given.  Based upon the 
assumption that the effect of n equally sized fractions and 𝑑 equally dosed 
fractions, and if repair of sublethal damage between fractions between 
fractions is complete and the proliferation during radiation treatment course 
can be ignored, the above equation (3.1) can transcribe as equation (3.2): 
𝑁 = 𝑁0{𝑒𝑥𝑝(−α𝑑 − β𝑑
2)}𝑛      (3.2) 
here, the effect (E) of multiple fractions in a multidose schedule can be 
expressed as equation (3.3): 
𝐸 = −ln{𝑒𝑥𝑝(−α𝑑 − β𝑑2)}𝑛 = 𝑛(α𝑑 + β𝑑2)    (3.3) 
then, from the relation 𝐷 = 𝑛𝑑 ; the above equation (3.2) and (3.3) can 
transcribe as equation (3.4) and (3.5): 
𝐸 = (α𝐷 + β𝑑𝐷)       (3.4) 
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𝑁 = 𝑁0𝑒𝑥𝑝(−𝐸) = 𝑁0𝑒𝑥𝑝(−α𝐷 − β𝑑𝐷) = 𝑁0𝑒𝑥𝑝 {−𝛼𝐷 (1 +
𝛽
𝛼
𝑑)} (3.5) 
Then, the Poisson probability of there being zero surviving cells at the end 
of a fractionated treatment course is given as the tumour control probability 
(TCP) shown in equation (3.6): 
TCP = exp [𝑁0𝑒𝑥𝑝 {−𝛼𝐷 (1 +
𝛽
𝛼
𝑑)}]     (3.6) 
where TCP equals the tumour control probability; the other parameters are 
mentioned in equation (3.1) through equation (3.5). 
For the evaluation of the radiation sensitivities of different cell cultures, 
the data obtained from 15, 34, and 21 different cell lines in normoxic, hypoxic, 
and hypoxic cell culture plus radiosensitizer were analysed respectively.  For 
each cell line, the SF (survival fraction) after a single fraction dose was 
calculated and entered into the model.  Then, the dose survival data for each 
in vitro cell culture experiment was fitted by the model, and biological 
parameters such as α, β, 𝐷50, and γ were determined.  A value of 𝐷50 and 
γ  represented the dose and steepness of a dose-response level on the 
assumption that survival fraction equals to 0.5, respectively.  
3-2-4. Statistical analysis 
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Exponential regression analyses were used to assess α and β coefficients, 
respectively.  Statistical comparisons of mean values were calculated using 
a two-sample independent t-test.  All the data were analyzed using 
OriginLab (OriginLab Corporation, Northampton, MA) scientific graphing 
and statistical analysis software.  A p-value of less than 0.05 was considered 
statistically significant.  
 
3-3. RESULTS 
3-3-1. Radiation response of the single cell 
Figure 6 shows cell survival after single-dose fraction in different cell 
cultures.  In figure 7, fitted curves using median parameter values of the α 
and β coefficients from exponential regression analysis (solid line and dotted 
line, respectively), and the effect of each coefficient on the curves ( α 
contribution: dark gray, β contribution: light gray) are presented.  As can be 
seen from these figures, ETZ enhanced the radiosensitivity of EMT6 in a dose-
dependent manner under hypoxic conditions.  The variations in predicted 
survival at higher single doses may increase; however, this increase could be 
suppressed by radiosensitizers. 
 25 
 
3-3-2. Comparisons of radiobiological parameters 
The radiobiological parameters from these experiments are summarized in 
Table I.  The α parameters (mean ± SD) were 0.257 ± 0.188 Gy-1, 0.078 ± 
0.080 Gy-1, and 0.182 ± 0.116 Gy-1 in normoxic cell, hypoxic cell, and hypoxic 
cell plus ETZ cultures, respectively.  The β parameters (mean ± SD) were 
0.0159 ± 0.0208 Gy-2, 0.0076 ± 0.0113 Gy-2, and 0.0062 ± 0.0077 Gy-2, 
respectively.  The 𝐷50 parameters (mean ± SD) were 3.2 ± 2.5 Gy, 6.4 ± 2.7 
Gy, and 3.7 ± 1.4 Gy, respectively.  The α and 𝐷50 values were significantly 
different between the normoxic cell culture and hypoxic cell culture (p < 0.01), 
respectively. 
3-3-3. Effects of cell survival and tumour control probability on variation in 
radiobiological parameters  
Figure 7 shows that when the α coefficient values fix (light gray), the 
variations in cell survival curves at high doses increase; as a function of the 
β coefficient values (dark gray) showing a similar trend in all cell cultures.  
Figure 8A-C demonstrate that the effects of α and β coefficients parameters 
on tumour control probabilities (gray shaded area).  Under hypoxic 
conditions, the mean values of α and β coefficients were smaller, and the 
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𝐷50 were much higher than under normoxic conditions as shown in Table I.  
It is apparent that the tumour control probabilities under such conditions 
were much lower than that at the same dose under normoxic conditions.  The 
number of cells (proxy for tumour size) is another clinical factor of 
radioresistance, albeit less efficient than the variations of α  and β 
coefficients for detecting early cancer (𝑁0 ≤ 10
8) as shown in Figure 8D-F. 
 
3-4. DISCUSSION 
The LQ formalism with α and β coefficients provides quantification of 
radiobiological response, which describes the radiation inactivation of 
different intrinsic cellular radiosensitivity.  However, in clinical situations, 
some factors such as inappropriate derivation of α/β ratios from single in 
vitro assays, clarification of radiation-induced late effects, and variations in 
individual α/β  ratios might cause unclear interpretation of the results 
obtained from early-responding and late-responding tissues (35). 
Although the α coefficient is relatively constant throughout the interphase 
of the cell cycle (36), the intra-tumour heterogeneity could cause variations in 
intrinsic radiosensitivity at a single fraction dose.  Our data show that the 
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variation of the α coefficient was nearly the same as that in previous studies 
(37).  Consequently, it is suggested that the variation in the α coefficient is 
in the same order as the radiosensitivity exhibited by asynchronous 
populations.  The β  coefficient might be relatively invariant, and its 
contribution to cell death is much smaller at conventionally fractionated 
treatment (38).  However, hypofractionated protocols in which implemented 
of recent clinical studies, the β  coefficient contributes to cell death by 
quadratic function so that it might not be negligible. 
Wide ranges of the α/β ratios, which can lead to a cell-lethal dose, are 
shown in our study, including a negative value.  It appears that a negative 
β coefficient causes these results, which may cause different sensitivities of 
the cells in the heterogeneous populations at the high dose region.  Moreover, 
in the curve fitting process, the data is often more complex than that 
described using the linear quadratic equation.  In the case of single very 
high-dose fraction experiments, the survival curve might be dependent on the 
experimental conditions. 
Figure 6 shows the radiosensitivities in different cell cultures.  The 
hypoxic cells appear twice as radioresistant as normoxic cells at survival 
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fraction.  Intra-tumour hypoxic cells proportions are an important 
complicating factor in cancer therapy and are an important target for 
anticancer drug design (39).  Our results show that the use of ETZ in hypoxic 
conditions improved the radiosensitivity of enhancement ratio (ER) of 1.72 at 
mean survival fraction, a value almost equal to a previous study (40).  
Hypoxic cells, which represent one source of tumour heterogeneity, can lead 
to flat response and survival curves with low α coefficient.  The effects of 
the variations of α and β coefficients, if either one fix to the median value, 
are shown in Figure 7.  In hypoxic conditions, the effects of radiosensitizing 
by ETZ are proved to increase the α coefficient, with a decrease of variations 
in the α  and β  coefficients.  However, in such conditions, the β 
coefficient’s contribution of radiosensitivity was relatively small.  
Consequently, the results suggest that ETZ could lead to improvement of 
tumour heterogeneities at high doses, including the change of oxygen tension 
and electron affinity.  
Figure 8 shows the variations of calculated tumour control probability 
(TCP) curves accounting for the discrepancies between α and β coefficients 
and cell numbers (tumour volume).  Several authors have pointed out that a 
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precise prediction could potentially be possible by assuming the distribution 
of intrinsic radiosensitivity at various cellular circumstances (30, 41).  Other 
important factors for determining the TCP is the number of cells that should 
be killed to result in a tumour cure; studies have shown a consistent cell 
density of 0.5–1.0 × 106/g (42, 43).  Consequently, the number of cells would 
be in the order of 107–109 in a typical tumour volume of 0.01–100 ml in clinical 
settings. Also, non-proliferating tumour cells are considered to be more 
resistant to radiation than that by proliferating cells (44).  Proliferation is a 
critical factor influencing the TCP, especially at highly fractionated treatment 
schedules (45).  It also could be reasonable to consider that the variations of 
intrinsic radiosensitivities of cells in vitro, tumour cells extracted by biopsy, 
or the use of tumour-bearing chick embryo (46) could predict the radiation 
response of like cells in vivo.  The purpose of this study is not to claim that 
we fully understand how to model the precise radiation response, but rather 
to show the relevant biophysical parameters are useful for predicting tumour 
response.  
 
 
 30 
 
Chapter 4 
Effects of uncertainties of radiosensitivity of  
biophysical modeling for treatment planning 
 
4-1. Introduction 
  The components of radiotherapy treatment plan mostly depend on the 
empirically defined by clinical protocols.  In such a situation, the appropriate 
prescription dose to the tumour, fraction size of the dose, fraction times and 
irradiation techniques are often determined by evaluating the calculated 3-
dimensinal dose distribution and clinical state/staging of each patient.   
Development of technological advances in radiotherapy makes possible to 
improve the radiation dose distribution that enabled fewer patients’ toxicity 
than conventional radiotherapy.  However, there have been still clinical 
failures in radiotherapy at a certain level due to several factors such as 
radioresistance (47, 48) and limitation of cytotoxic dose to the tumour owing 
to the damage to the normal tissue (49, 50).  Furthermore, the application of 
more advanced radiotherapy techniques has led to more complex and 
heterogeneous radiation dose distribution, which may cause to the 
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intercellular variation of radiation response in the tumour and normal tissues.  
Ideally, these clinical practices would be desirable to make an accurate 
prediction for curative intent, while excluding uncertainties of the clinical 
failures with quantitative approach.   
Applying a radiobiological model such as TCP/NTCP model (as described in 
Chapter2-2-4 to 2-2-5) for radiotherapy is one of the methods to rank several 
treatment plans.  However, the predictive capabilities of current models are 
still under development (51, 52) because there is still insufficient reliable data 
on the characteristics of human tissues and tumours in clinical radiotherapy. 
 The aim of this study was to assess the usefulness of TCP/NTCP model 
and stochastic biological model applying for Gaussian distribution as the 
intercellular uncertainty of tumour in the treatment planning. 
 
4.2. Materials and Methods 
4-2-1. Application for treatment planning 
  For biological evaluation in a treatment planning, we used clinical three-
dimensional radiotherapy treatment planning system with function of 
biological evaluation analysis (Eclipse ver.11.0, Varian medical systems, US).  
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In the planning system, biological parameters such as α/β ratio, γ, 𝐷50 can 
be set to any given values to calculate the tumour control probability (TCP) 
(Figure 9). 
4-2-2. Phantom 
  Firstly, we have prepared a digital voxel phantom of 10 x 10 x 10 cm3 with 
a sphere target of 1 cm in diameter placed at a center of the phantom.  Then, 
the dose calculation with a four-field technique was performed (Figure 10a).  
Secondly, we have simulated a prostate cancer patient of demo data. Then 
after, the radiation dose calculation with VMAT was performed (Figure 10b). 
4-2-3. Beam data 
  All beam data for calculation of radiation dose distribution used in this 
study were 6 MV photon beam of Novalis-Tx (BrainLab, US) commissioned 
for clinical use.   
4-2-4. Dose fraction protocols and biologically effective dose 
  Dose fraction protocols in this analysis were set as below. 70 Gy/35 fr, 72 
Gy/36 fr, 74 Gy/37 fr, 76 Gy/38 fr, 78 Gy/39 fr, 72 Gy/40 fr, 73.8 Gy/41 fr, 45.6 
Gy/42 fr, 77.4 Gy/43 fr, 79.2 Gy/44 fr, 81 Gy/45 fr, 52.5 Gy/20 fr, 57 Gy/19 fr, 
60 Gy/20 fr, 62 Gy/20 fr, 56 Gy/16 fr, 63.2 Gy/20 fr, 66 Gy/22 fr, 35 Gy/5 fr, 
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37.5 Gy/5 fr and 40 Gy/5 fr of five daily fractions in a week.  These dose 
fraction protocols were divided into three types of group; conventional 
fractionation (70 Gy/35 fr, 72 Gy/36 fr, 74 Gy/37 fr, 76 Gy/38 fr, 78 Gy/39 fr, 
72 Gy/40 fr, 73.8 Gy/41 fr, 45.6 Gy/42 fr, 77.4 Gy/43 fr, 79.2 Gy/44 fr, 81 Gy/45 
fr), intermediate hypofractionation (52.5 Gy/20 fr, 57 Gy/19 fr, 60 Gy/20 fr, 62 
Gy/20 fr, 56 Gy/16 fr, 63.2 Gy/20 fr, 66 Gy/22 fr), hypofractionation (32.5 Gy/5 
fr, 35 Gy/5 fr, 37.5 Gy/5 fr and 40 Gy/5 fr), respectively.  As concern to these 
protocols, we calculated biologically equivalent dose (BED) by the following 
equation. 
𝐵𝐸𝐷 = 𝐷 (1 +
𝑑
𝛼/𝛽
)           (2.15) 
where D is the total dose.  The parameter d is dose per fraction.  BED3 
(often discussed as lower 𝛼/β ratio in prostate cancer) and BED10 (typical 
α/β  in cancer) are calculated in case the α/β  ratio is set to 3 and 10, 
respectively. 
4-2-5. Biological parameters 
  In all calculation for TCP analysis, we have assumed that the tumour is 
prostate cancer (clinical stage of B).  The default parameters setting of 𝐷50, 
γ, α/β ratio for the stage were 52.7 Gy, 4.2 and 10 Gy, respectively.  Also, all 
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calculation for NTCP analysis were performed as to the grade 2 or greater 
late rectum toxicity and the grade 3 or greater late bladder toxicity.  The 
default parameters setting of n, m, α/β ratio were 0.29, 0.22 and 3.0 Gy for 
rectum, and 0.13, 0.11 and 6.0 Gy for bladder, respectively. 
4-2-6. Hypothesis of intercellular uncertainties of radiation sensitivity 
According to our basic experiments result in our study described in Chapter 
3, we hypothesized these biological parameters had Gaussian distribution 
with a certain amount of range (0 %-50 % for α/β radio and 0 %-30% for other 
parameters) based on their default value.  Then, we have re-evaluated TCP 
and NTCP variations of the tumour.   
 
4-3. Results 
4-3-1. Effects of biologically equivalent dose in clinical protocols  
The second and the third column in Table II-IV show BED10 and BED3 of 
clinical protocols calculated with the α/β  ratio of 10 and 3, respectively.  
Both BED10 and BED3 increase as the higher total dose with the same dose 
fraction size.  However, BED10 decreases in high dose fraction size 
(hypofractionation) at a particular range of total dose, contrary to BED3 that 
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increases. 
4-3-2. Effects of TCP and NTCP due to biological parameters in clinical 
protocols 
  Figure 11 shows variations of tumour control probability (TCP) with 
calculated BED10 of clinical protocols and radiobiological parameters using a 
digital phantom (a) and a patient data (b).   
  TCP values mostly depended on the BED10 (i.e. irradiated dose to the 
volume of tumor), which contributed to the cell killing of the tumour directly.  
As respect to the differences of the α/β  ratio, 𝐷50  and γ value, these 
parameters slightly affected the TCP (i.e. the lower value of these parameters 
made the TCP worse, especially in the case of lower BED10 both phantom and 
patient study).   
Figure 12 shows variations of normal tissue complication probability 
(NTCP) with calculated BED3 of clinical protocols and radiobiological 
parameters using a patient data as to (a) the rectum and (b) the bladder. 
NTCP values mostly depended on the BED3 (i.e. irradiated dose to the 
volume of normal tissues), which contributed to the cell killing or cell 
repairing of the normal tissues directly as to the α/β ratio.  As respect to 
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the differences of n and m value, these parameters strongly affected to the 
NTCP (i.e. the lower value of n made the NTCP worse, in contrast to the 
smaller value of m that made the NTCP better, regardless of the value of 
BED3 in these clinical protocols). 
4-3-3. Variation of TCP and NTCP due to uncertainties of biological 
parameters 
Table II shows The impacts of TCP loss/profit using the Gaussian 
distributions for radiobiological parameters with patient data.  Variations of 
TCP intricately depended on the clinical protocols and the uncertainties of 
the parameters.  The contributions to the variation of TCP were much higher 
with the uncertainties of 𝐷50 rather than that of α/β ratio and γ.   
Table III and IV show the impact of NTCP loss/profit using the Gaussian 
distributions for radiobiological parameters with patient data.  Variations of 
NTCP less depended on the clinical protocols and the uncertainties of the 
parameters compared to that of TCP.  The contributions to the variation of 
NTCP were much higher as to the bladder than the rectum in a small range.  
Moreover, these were much affected by the uncertainties of the value of α/β 
ratio rather than that of the value of m and n in the case of a hypofractionated 
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protocol with higher total dose.  
Our data suggested that these uncertainty effects would be relatively small 
in conventionally fractionated treatments with 74-78 Gy/35-39 fr or 75.6-81 
Gy/45 fr.  However, in the case of a hypofractionated protocol such as 40 Gy/5 
fr, the effects would be slightly greater in both TCP and NTCP.  From these 
results, the increase of total radiation dose, as well as precise determination 
of these biological parameters, would minimize these impacts.   
 
4-4. Discussion 
A α/β ratio is often used to estimate the effects of radiation on various 
tissues and compare various dose and clinical protocols.  The α/β ratio is 
defined to be 10 Gy for early-responding tissues and tumour, 3–5 Gy for late 
responding tissues in clinical situations.  However, our study has shown the 
variation and difference of a α/β ratio, 𝐷50, γ in the tumour compared to 
above fixed value, which has strongly affected by the probability of cell death 
and cure.   
Based on the experimental biological theory, it has been suggested that 
altered fractionation schemes potentially may have further therapeutic gains.  
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However, conventionally fractionated treatments often use 1.8 Gy-2 Gy for 
each fraction and daily 5 times per week has standardized for the 
administration of acute and late reactions of normal tissues (53).  In many 
clinical situations, a certain amount of total given dose with conventionally 
fractionated treatments is defined as standard radiotherapy that depends on 
the treatment site, clinical staging, combined therapy and so on.  
In recent clinical studies, the lower α/β ratio of prostate cancer causes 
much discussion of more efficient treatment such as hypofractionated 
protocols (54-58).  The hypofractionated scheme seemed to have advantages 
for the variations of α/β  ratios in the tumor cells while conventionally 
fractionated treatments appeared to have disadvantages for the variations of 
𝐷50.  Therefore, conventionally fractionated treatments based on large α/β 
ratios (=10 Gy) may not be optimal for the prostate cancer treatment protocols.  
For more precise prediction of such as optimal protocols, tumour control, and 
normal tissue complication, treatment planning systems should be 
incorporated TCP and NTCP into the optimization in clinical practice.  
However, at a low dose per fraction less than 1.0 Gy, the standard LQ model 
might considerably underestimate the biological effect of a given total dose 
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because of the DNA repair of the cells (59).  Also, a shorter fraction scheme 
might prevent compensatory proliferation as in acute effects so that it might 
increase the severity of the normal tissue reactions (60).  
Moiseenco reported that the impact of the heterogeneity of prostate cancer 
cells for low α/β ratio did cause few losses of TCP (61).  Xiong et al. reported 
a similar study to above that the impact of the heterogeneity of prostate 
cancer patients that assumed for low α/β ratio with different fraction scheme 
(62).  They concluded that the heterogeneity has some effects on 
hypofractionated treatments for high α/β ratio.  However, hypofractionated 
treatment can be ensured with some extra dose even when the α/β ratio has 
large errors clinically.  There have been some approaches for improved 
biophysical models instead of LQ model (63-65).  However, Shuryak et al. 
reported that distinct tumoricidal mechanisms do not determine tumor 
control at hypofractionated protocol (66).  Our results also suggested that 
the heterogeneities of the α/β ratios in the tumour cells might not affect to 
TCP significantly, except for in case of above mentioned hypofractionated 
treatments for high α/β ratio.   
Whereas, Ray et al. suggested that if the α/β ratios are not accurately 
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specified and not selected dose fractionations by hypofractionated schedule 
appropriately, all treatments might increase normal tissue complications 
unnecessarily (67).  Olivotto et al. reported that patients underwent 
hypofractionated protocol with multiple fractions per day for breast cancer 
treatments suffered from greater normal tissue toxicity than those in the 
control protocol (68).  Arcangeli et al. also reported that equivalent late 
toxicity effects between the hypofractionated and conventionally fractionated 
protocols for prostate cancer treatments and significantly higher freedom 
from biochemical failure for the hypofractionated protocol (69).  Our results 
also suggested that the heterogeneities of the α/β  ratios in the normal 
tissues especially the rectum and bladder for prostate cancer treatments 
might affect to increase of NTCP in hypofractionated protocols.   
We have challenged to apply these uncertainties for the biological model of 
prostate cancer treatment protocol in this study.  However, there are many 
factors of uncertainties related to radioresistance such as radiation-induced 
bystander effect (70, 71), the environment of cell circumstances of hypoxia (39, 
72), cancer stem cell (48, 73) and so on.   
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Chapter 5 
Conclusions 
 
In conclusion, our preliminary results have suggested that using the 
distributions of the biological parameter values in the biophysical modeling, 
we can evaluate the effects of intercellular radiosensitivity uncertainty for 
the applications of clinical radiotherapy treatment planning.  Further 
advancement would benefit from additional experiments employing different 
tumour models, and thus, in vivo studies are necessary to develop this 
modeling.  The result from a fundamental study using EMT6 cells, the α 
coefficient and the dose that killed half of the clonogenes population (𝐷50) 
were significantly different between the normoxic and the hypoxic cell 
cultures (p<0.01), respectively.  The use of radiosensitizers under the 
hypoxic conditions improved radiosensitivity.   
Our data have suggested that the optimal fractionation protocol in the 
treatment of prostate cancer relates to the value and uncertainties of 
biological parameters such as α/β ratio, γ, and 𝐷50, respectively.  Also, it is 
indicated that the contributions to the variation of TCP were much higher 
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with the uncertainties of 𝐷50  rather than that of α/β  ratio and γ .  
Therefore, if α/β ratio of prostate cancer is lower than that of normal tissues 
such rectum and bladder, hypofractionated protocols that could increase the 
biologically equivalent dose as compared to standard protocols would result 
in an improved therapeutic ratio.  Our data and several studies showed that 
hypofractionated schedule treatments with uncertainties of biological 
parameters might increase normal tissue complications unnecessarily.   
However, our study did not mention the factors of uncertainties related to 
radioresistance such as radiation-induced bystander effect, the environment 
of cell circumstances of hypoxia, cancer stem cell and so on.  Several clinical 
studies suggested that hypofractionated protocols would have benefit for low 
α/β ratio tumor such as prostate cancer treatment with capable of reducing 
normal tissue complication (74, 75).  The challenges to apply these 
uncertainties for the biological model of various clinical protocols are further 
studies.  
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Summary 
 
Radiotherapy has developed as primary treatment options for cancer 
along with surgery and chemotherapy.  Recently, more than half of all 
cancer patients have receiving radiation therapy during their course of 
illness.  Theoretical studies based on the in vitro experiments in 
radiobiology have contributed to the development of radiotherapy.  
However, few of these still have led to demonstrable clinical gains.   
In macroscopic viewpoint, it can be clear that the surviving cells would 
decrease by a certain amount of radiation dose.  In contrast, it is 
challenging that in microscopic viewpoint, no one still predict which cell die 
or survive by radiation.  These uncertain phenomena would be needed a 
much more robust and relevant parameter to assess radiation effect 
stochastically since any cell that retains proliferative capacity can cause 
failure to cancer treatment. 
 In this thesis, we investigate the distribution of uncertainty of cell survival 
due to radiation and application of treatment planning.  Firstly, we 
evaluated the distribution of uncertainty of cell survival due to radiation and 
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assessed the predictions of tumour response using three different in vitro 
experimental cell cultures with EMT6/KU mouse mammary tumour cells.  
We then discussed the relationship between in vitro radiosensitizing 
activities with etanidazole (ETZ) and uncertainties in characteristics of cell 
survival using radiobiological parameters.  Secondary, we assessed the 
usefulness of TCP/NTCP model and stochastic biological model applying for 
Gaussian distribution as the intercellular uncertainty of tumour in the 
treatment planning.   
The result from a fundamental study using EMT6 cells showed that the α 
parameters (mean ± SD) were 0.257 ± 0.188 Gy-1, 0.078 ± 0.080 Gy-1, and 0.182 
± 0.116 Gy-1 in normoxic cell, hypoxic cell, and hypoxic cell plus ETZ cultures, 
respectively.  The β parameters (mean ± SD) were 0.0159 ± 0.0208 Gy-2, 
0.0076 ± 0.0113 Gy-2, and 0.0062 ± 0.0077 Gy-2, respectively.  The 𝐷50 
parameters (mean ± SD) were 3.2 ± 2.5 Gy, 6.4 ± 2.7 Gy, and 3.7 ± 1.4 Gy, 
respectively.  The α and 𝐷50  values were significantly different between 
the normoxic cell culture and hypoxic cell culture (p < 0.01), respectively.  
The use of radiosensitizers under the hypoxic conditions improved 
radiosensitivity. 
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  The result from an application study using the treatment planning showed 
that TCP values mostly depended on the BED10 (i.e. irradiated dose to the 
volume of tumor), which contributed to the cell killing of the tumour directly.  
NTCP values mostly depended on the BED3 (i.e. irradiated dose to the volume 
of normal tissues), which contributed to the cell killing or cell repairing of the 
normal tissues directly as to the α/β ratio.  Our data have suggested that 
the optimal fractionation protocol in the treatment of prostate cancer relates 
to the value and uncertainties of biological parameters such as α/β ratio, γ, 
and 𝐷50 , respectively.  Also, it is indicated that the contributions to the 
variation of TCP were much higher with the uncertainties of 𝐷50 rather than 
that of α/β ratio and γ.  However, our study did not mention the factors of 
uncertainties related to radioresistance such as radiation-induced bystander 
effect, the environment of cell circumstances of hypoxia, cancer stem cell and 
so on.  Several clinical studies suggested that hypofractionated protocols 
would have benefit for low α/β ratio tumor such as prostate cancer treatment 
with capable of reducing normal tissue complication.  Our data suggested 
that these uncertainty effects would be relatively small in conventionally 
fractionated treatments with 74-78 Gy/35-39 fr or 75.6-81 Gy/45 fr.  However, 
 46 
 
in the case of a hypofractionated protocol such as 40 Gy/5 fr, the effects would 
be slightly greater in both TCP and NTCP.  From these results, the increase 
of total radiation dose, as well as precise determination of these biological 
parameters, would minimize these impacts.  Also, our data and several 
studies showed that hypofractionated schedule treatments with uncertainties 
of biological parameters might increase normal tissue complications 
unnecessarily.   Therefore, the challenges to applying these uncertainties for 
the biological model of various clinical protocols are further studies.  
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Figure 1.  The time frames for effects of radiation.  
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Figure 2.  Time-course of radiation response in tumour and normal tissue. 
(a) The temporal response and (b) the collective response.  
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Figure 3.  The concept of radiation damage to DNA.  Clustered and 
isolated DNA damage often induce DNA single and double strand breaks.  
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Figure 4.  The concept of target theory. (a) single target single hit model.  
(b)multi-target single hit model. 
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Figure 5.  The concept of linear-quadratic (LQ) model. 
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Figure 6.  Surviving fractions of EMT6 cells in vitro under normoxia, 
hypoxia, and hypoxia plus etanidazole (ETZ) culture.  Fitted curves (solid 
line) represent the approximated curves of the α and β coefficients from 
the exponential regression analysis. 
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Figure 7.  Surviving fractions of EMT6 cells in vitro for cells cultured under normoxic (a), hypoxic (b), and hypoxic 
plus etanidazole (ETZ) (c) conditions.  Fitted curves (solid line) represent the approximated curves of the α and β 
coefficients from exponential regression analysis (solid line and dotted line).  The effect of each coefficient on the 
curves is represented by dark gray shading for the α contribution and by light gray shading for the β contribution 
with 95% confidence intervals (CI), respectively. 
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Figure 8.  Variations of calculated tumour control probability curves for EMT6 cells in vitro for normoxic (a, d), 
hypoxic (b, e), and hypoxic plus etanidazole (ETZ) (c, f) culture related to the α and β coefficients and cell numbers.  
Fitted curves (solid line) in a-c represent the approximated curves of the α and β coefficients from exponential 
regression analysis with 95% confidence intervals (CI) (gray shaded area) in the case of N0 = 108, respectively. 
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Figure 9.  The setting of biological parameters in the treatment planning system(a) and the variations of calculated 
tumor control probability as respect to (b) α/β ratios, (c) 𝐷50 values and (d) gamma values.  
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Figure 10.  Application for treatment planning by use of a digital phantom (sphere target of φ1cm)(a) and a patient 
data(b), respectively.  
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Figure 11.  Relationship of tumour control probability between the values of α/β ratio, γ, and 𝐷50 was evaluated by 
calculated BED10 of each clinical protocols from fraction dose by using a digital phantom(a) and a patient data(b), 
respectively.  
a) Digital phantom
a) Patient data
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Figure 12.  Relationship of normal tissue complication probability between the values of n, m, and α/β ratio was 
evaluated by calculated BED3 of each clinical protocols from fraction dose by using a patient data as to (a) the rectum 
and (b) the bladder.   
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Table I.  Radiobiological parameters of intrinsic in vitro radiosensitivity of EMT6 cells. ETZ: Etanidazole. *p<0.01 
compared to normoxic cell culture.   
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Table II.  The effects of TCP loss/profit taking into account for the Gaussian distribution for radiobiological 
parameters compared to fixed value of each parameter at different dose fraction protocols.  
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Table III.  The effects of NTCP loss/profit taking into account for the Gaussian distribution for radiobiological 
parameters compared to fixed value of each parameter at different dose fraction protocols as to the rectum.  
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Table IV.  The effects of NTCP loss/profit taking into account for the Gaussian distribution for radiobiological 
parameters compared to fixed value of each parameter at different dose fraction protocols as to the bladder.   
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